At the 2023 Bio-Europe Spring, RudaCure was represented by CEO Yongho Kim and Research Strategy Team Leader Hawon Jeon, who held a meeting with Ceva, a French company currently exploring co-development of RCI001 for veterinary medicine.
The meeting provided an opportunity to discuss future joint commercialization directions with Ceva representatives and to exchange information that both companies need to share.
Many companies showed interest in RCI001 for dry eye disease and productive discussions were held. For RCI002, the pain treatment, Italian company Dompe and the long-established German company Grünenthal expressed interest and agreed to continue discussions on the drug.
